Intravenous immunoglobulin as sole therapy for systemic vasculitis

Area of Science:

• Immunology
• Rheumatology
• Nephrology

Background:

• Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) are ANCA-associated vasculitides.
• High-dose intravenous immunoglobulin (IVIg) is an established treatment for refractory WG/MPA when used with immunosuppression.

Purpose of the Study:

• To evaluate the efficacy of IVIg monotherapy in early-stage, treatment-naive patients with ANCA-positive vasculitis.
• To assess the safety and tolerability of IVIg as a sole therapeutic agent in this patient cohort.

Main Methods:

• A prospective study involving six new patients with early ANCA-positive vasculitis.
• Treatment with high-dose, pooled, i.v. immunoglobulin (IVIg) alone, without concurrent immunosuppression.
• Monitoring of disease activity, clinical response, and adverse events.

Main Results:

• IVIg was well tolerated by all patients.
• Early reductions in disease activity were observed in all six patients.
• Four patients achieved full clinical remission lasting at least one year; two experienced partial, transient responses requiring conventional treatment.
• Relapse occurred in two of the four initially remitting patients after 16-48 months; two remained in remission.

Conclusions:

• IVIg monotherapy can induce remission in a subset of patients with early ANCA-positive vasculitis.
• While IVIg is generally safe and well-tolerated, its efficacy as monotherapy may be limited, with a significant risk of relapse.
• Further research is needed to identify predictors of response and long-term outcomes for IVIg monotherapy in vasculitis.